IL243687A0 - For the treatment of multiple myeloma 1–cs antibodies against - Google Patents

For the treatment of multiple myeloma 1–cs antibodies against

Info

Publication number
IL243687A0
IL243687A0 IL243687A IL24368716A IL243687A0 IL 243687 A0 IL243687 A0 IL 243687A0 IL 243687 A IL243687 A IL 243687A IL 24368716 A IL24368716 A IL 24368716A IL 243687 A0 IL243687 A0 IL 243687A0
Authority
IL
Israel
Prior art keywords
antibodies
treatment
multiple myeloma
myeloma
Prior art date
Application number
IL243687A
Other languages
English (en)
Hebrew (he)
Original Assignee
Abbvie Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/842,011 external-priority patent/US20050025763A1/en
Priority claimed from US10/982,357 external-priority patent/US7709610B2/en
Application filed by Abbvie Biotherapeutics Inc filed Critical Abbvie Biotherapeutics Inc
Publication of IL243687A0 publication Critical patent/IL243687A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL243687A 2004-03-29 2016-01-19 For the treatment of multiple myeloma 1–cs antibodies against IL243687A0 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US55762004P 2004-03-29 2004-03-29
US55762204P 2004-03-29 2004-03-29
US55762104P 2004-03-29 2004-03-29
US10/842,011 US20050025763A1 (en) 2003-05-08 2004-05-07 Therapeutic use of anti-CS1 antibodies
US10/982,357 US7709610B2 (en) 2003-05-08 2004-11-05 Therapeutic use of anti-CS1 antibodies
PCT/US2004/037430 WO2005102387A2 (en) 2004-03-29 2004-11-08 Therapeutic use of anti-cs1 antibodies

Publications (1)

Publication Number Publication Date
IL243687A0 true IL243687A0 (en) 2016-04-21

Family

ID=44597272

Family Applications (1)

Application Number Title Priority Date Filing Date
IL243687A IL243687A0 (en) 2004-03-29 2016-01-19 For the treatment of multiple myeloma 1–cs antibodies against

Country Status (8)

Country Link
JP (1) JP4758984B2 (enrdf_load_stackoverflow)
CY (1) CY1115003T1 (enrdf_load_stackoverflow)
DK (1) DK2301576T3 (enrdf_load_stackoverflow)
ES (1) ES2393539T3 (enrdf_load_stackoverflow)
HR (1) HRP20120975T1 (enrdf_load_stackoverflow)
IL (1) IL243687A0 (enrdf_load_stackoverflow)
PT (1) PT2301576E (enrdf_load_stackoverflow)
SI (1) SI2301576T1 (enrdf_load_stackoverflow)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3138282A1 (en) * 2008-06-02 2009-12-10 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
EP3919069A1 (en) 2012-11-05 2021-12-08 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
WO2015166056A1 (en) * 2014-05-02 2015-11-05 Cellectis Cs1 specific multi-chain chimeric antigen receptor
FI3794042T3 (fi) 2018-05-18 2024-05-31 Daiichi Sankyo Co Ltd Anti-muc1-eksatekaani-vasta-aine-lääkekonjugaatti
CN112442126B (zh) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020123617A1 (en) * 1999-12-23 2002-09-05 Starling Gary C. Novel immunoglobulin superfamily members of APEX-1, APEX-2 and APEX-3 and uses thereof

Also Published As

Publication number Publication date
HK1099699A1 (en) 2007-08-24
ES2393539T3 (es) 2012-12-26
HRP20120975T1 (hr) 2013-01-31
JP4758984B2 (ja) 2011-08-31
PT2301576E (pt) 2012-12-20
HK1155670A1 (en) 2012-05-25
CY1115003T1 (el) 2016-12-14
JP2007530675A (ja) 2007-11-01
SI2301576T1 (sl) 2013-02-28
DK2301576T3 (da) 2012-12-10

Similar Documents

Publication Publication Date Title
IL284991A (en) Antibodies against cd38 for treatment of multiple myeloma
IL181575A0 (en) Anti-ox40l antibodies
IL228032A0 (en) Antibodies
EP1869192A4 (en) FRAME MIXTURE OF ANTIBODIES
GB0420466D0 (en) Anti-glucan antibodies
EG25401A (en) Process for the preparation of urea.
IL243687A0 (en) For the treatment of multiple myeloma 1–cs antibodies against
ZA200701952B (en) Anti-OX40L antibodies
PT1962913E (pt) Radioimunoconjugado para cd66 humano para o tratamento de mieloma múltiplo
GB0400802D0 (en) Compounds for the treatment of disease
HUP0401379A3 (en) Process for the preparation of risperidon
ZA200606780B (en) Compounds for the treatment of diseases
IL178960A0 (en) Process for the preparation of pyridin-2-ylmethylsulphinyl-1h-benzimidazol compounds
HK40116860A (en) Antibodies against cd38 for treatment of multiple myeloma
HUS1700054I1 (hu) CD38-ellenes antitestek a mielóma multiplex kezelésére
SG10201610317VA (en) Antibodies against cd38 for treatment of multiple myeloma
SI1732916T1 (sl) Postopek za pripravo alkoksikarbonilmetoksi-ciklopentanov
GB0425064D0 (en) Compounds useful for the treatment of diseases
AP2006003743A0 (en) Compounds useful for the treatment of diseases
GB0425073D0 (en) Compounds for the treatment of diseases
GB0420867D0 (en) Compounds for the treatment of diseases
IL177531A0 (en) Compounds for the treatment of diseases
SI1951759T1 (sl) Protitelesa anti-EGFR
IL179092A0 (en) Spiroderivatives for the treatment of hypertension
PL369884A1 (pl) Sposób wytwarzania podstawionych cyjanowinylooksiranów